MELANOMA RESEARCH

metrics 2024

Leading the Charge in Melanoma Research Excellence.

Introduction

MELANOMA RESEARCH is a leading journal dedicated to the exploration and dissemination of innovative research in the field of melanoma and skin cancers. Published by Lippincott Williams & Wilkins, this journal has been a pivotal resource since its inception in 1991, continually evolving to encompass significant advancements within dermatology and oncology through 2024. With a focus on high-quality, peer-reviewed articles, it offers critical insights into cellular mechanisms, treatment strategies, and emerging therapies pertinent to melanoma. It currently holds a Q3 category in Cancer Research and a Q2 category in Dermatology, while also ranking within the 65th percentile for Medicine Dermatology according to Scopus. Although not an open-access journal, MELANOMA RESEARCH ensures accessibility through various institutional subscriptions, making it an invaluable asset for researchers, professionals, and students engaged in pioneering melanoma research.

Metrics 2024

SCIMAGO Journal Rank0.63
Journal Impact Factor1.50
Journal Impact Factor (5 years)1.90
H-Index80
Journal IF Without Self1.50
Eigen Factor0.00
Normal Eigen Factor0.41
Influence0.56
Immediacy Index0.40
Cited Half Life8.00
Citing Half Life6.80
JCI0.55
Total Documents2044
WOS Total Citations2333
SCIMAGO Total Citations14637
SCIMAGO SELF Citations693
Scopus Journal Rank0.63
Cites / Document (2 Years)1.44
Cites / Document (3 Years)1.77
Cites / Document (4 Years)1.96

Metrics History

Rank 2024

Scopus

Dermatology in Medicine
Rank #49/142
Percentile 65.49
Quartile Q2
Oncology in Medicine
Rank #231/404
Percentile 42.82
Quartile Q3
Cancer Research in Biochemistry, Genetics and Molecular Biology
Rank #167/230
Percentile 27.39
Quartile Q3

IF (Web Of Science)

DERMATOLOGY
Rank 59/94
Percentile 37.80
Quartile Q3
MEDICINE, RESEARCH & EXPERIMENTAL
Rank 140/189
Percentile 26.20
Quartile Q3
ONCOLOGY
Rank 259/322
Percentile 19.70
Quartile Q4

JCI (Web Of Science)

DERMATOLOGY
Rank 56/94
Percentile 40.43
Quartile Q3
MEDICINE, RESEARCH & EXPERIMENTAL
Rank 112/189
Percentile 40.74
Quartile Q3
ONCOLOGY
Rank 195/322
Percentile 39.44
Quartile Q3

Quartile History

Similar Journals

SEMINARS IN ONCOLOGY

Fostering Knowledge Exchange in Oncology Research
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0093-7754Frequency: 6 issues/year

SEMINARS IN ONCOLOGY is a premier journal in the field of oncology, published by W B Saunders Co-Elsevier Inc. With its ISSN 0093-7754 and E-ISSN 1532-8708, this esteemed publication has been contributing significantly to cancer research and education since its inception in 1974. The journal currently holds a distinguished position in the academic landscape, ranking in the Q1 category for Hematology and Q2 for Oncology, and featured prominently in Scopus rankings—34th out of 137 in Medicine Hematology, and 108th out of 404 in Medicine Oncology. SEMINARS IN ONCOLOGY aims to disseminate cutting-edge research, critical reviews, and innovative treatment approaches, making it an invaluable resource for researchers, healthcare professionals, and students dedicated to the fight against cancer. Although not an Open Access journal, it maintains a commitment to high-quality, peer-reviewed content, further solidifying its role as a vital reference point in oncological studies. The journal serves as a crucial platform for the exchange of knowledge, insights, and advancements that shape the future of cancer care.

Journal of Hematology & Oncology

Transforming Insights into Impactful Treatments
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

CANCER RESEARCH

Unlocking groundbreaking discoveries in cancer science.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 0008-5472Frequency: 24 issues/year

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.

Journal for ImmunoTherapy of Cancer

Advancing Breakthroughs in Cancer Immunotherapy
Publisher: BMJ PUBLISHING GROUPISSN: Frequency: 1 issue/year

Journal for ImmunoTherapy of Cancer, published by the esteemed BMJ Publishing Group, is a leading scholarly journal dedicated to advancing the field of immuno-oncology. Since its inception in 2013, this Open Access journal has emerged as a pivotal platform for disseminating cutting-edge research and innovative methodologies in cancer immunotherapy. With a remarkable impact factor and stellar rankings, including Q1 listings in multiple relevant categories such as Cancer Research, Immunology, and Molecular Medicine, it plays a crucial role in bridging the gap between basic immunology and clinical applications, thus fostering collaboration among researchers, healthcare professionals, and students. The journal's scope encompasses a diverse range of topics, focusing on the latest breakthroughs and experimental findings in cancer treatment, making it indispensable for those seeking to contribute to the evolving landscape of oncological sciences. Located in the United Kingdom at the British Medical Association House, the journal continues to serve as a valuable resource for those at the forefront of cancer research and therapy.

World Journal of Clinical Oncology

Illuminating the Path to Oncology Excellence
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 2218-4333Frequency: 12 issues/year

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

Case Reports in Oncology

Illuminating Pathways in Cancer Treatment
Publisher: KARGERISSN: 1662-6575Frequency: 3 issues/year

Case Reports in Oncology is a peer-reviewed journal published by KARGER, dedicated to the dissemination of high-quality case studies and clinical reports in the field of oncology. Since its transition to Open Access in 2008, this Swiss-based journal has aimed to broaden the accessibility of key findings to a global audience of researchers, healthcare professionals, and students. The journal is positioned in the Q3 quartile for oncology, indicating its valuable contribution to the field, while also holding a Scopus rank of 294 out of 404 in Medicine, with a percentile of 27%. However, its open access model ensures that even those outside of traditional academic institutions can engage with critical advancements and novel insights from the oncology community. With a publication span extending from 2010 to 2024, Case Reports in Oncology serves as a crucial platform for sharing unique clinical experiences and innovative treatment strategies, ultimately enriching the practice and study of oncology.

BREAST CANCER RESEARCH AND TREATMENT

Leading the Charge in Breast Cancer Innovation
Publisher: SPRINGERISSN: 0167-6806Frequency: 18 issues/year

Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.

Trends in Cancer

Uncovering Breakthroughs in Cancer Biology and Therapy
Publisher: CELL PRESSISSN: 2405-8025Frequency: 12 issues/year

Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.

World Journal of Oncology

Connecting insights to combat cancer effectively.
Publisher: ELMER PRESS INCISSN: 1920-4531Frequency: 12 issues/year

The World Journal of Oncology, published by ELMER PRESS INC, is a vibrant platform for disseminating groundbreaking research and advancements in the field of oncology. With its ISSN 1920-4531 and E-ISSN 1920-454X, this journal is dedicated to publishing high-quality studies that enhance our understanding of cancer and its treatment. The journal is recognized for its significant contributions, evidenced by its Q2 classification in both Cancer Research and Oncology categories in 2023, and accolades such as a Scopus rank of #126/404 in Medicine _ Oncology. Catering to the needs of researchers, professionals, and students, the World Journal of Oncology offers an essential resource for the latest scientific insights and clinical practices, ensuring the global oncology community remains informed and engaged. The journal operates under a selective publication model, maintaining rigor in peer review while facilitating knowledge sharing across converged years from 2014 to 2016 and 2020 to 2024, further establishing its importance in the ongoing fight against cancer.

Pigment Cell & Melanoma Research

Pioneering Discoveries in Melanoma and Skin Health.
Publisher: WILEYISSN: 1755-1471Frequency: 6 issues/year

Pigment Cell & Melanoma Research is a premier journal published by Wiley that serves as a vital resource for researchers, professionals, and students in the fields of biochemistry, genetics, molecular biology, dermatology, and oncology. With its ISSN of 1755-1471 and E-ISSN 1755-148X, the journal is recognized for its impactful contributions to advancing our understanding of pigment cells and melanoma, particularly from 2008 to 2024. The journal currently holds a commendable Q1 ranking across major categories, including dermatology and oncology, and demonstrates an impressive 96th percentile ranking in the field of medicine’s dermatology category. While the journal is not open access, it offers researchers valuable insights into the latest findings and innovations in skin biology and cancer research. By publishing rigorous peer-reviewed articles, Pigment Cell & Melanoma Research aims to foster collaboration and education within the scientific community, making it an indispensable tool for anyone dedicated to the study of pigmentation disorders and melanoma.